The Emperor of All Maladies, checked against care today

The Emperor of All Maladies: A Biography of Cancer is Siddhartha Mukherjee's history of cancer. Scribner published it in November 2010. It won the Pulitzer Prize for General Nonfiction in 2011. Mukherjee is an oncologist. As the subtitle suggests, the book is framed as a biography of the disease itself. It is not the story of one patient or one scientist.

It is not a memoir. Mukherjee draws on his own clinical training and his patients' cases throughout. But the organizing structure is historical and thematic. It traces how cancer has been understood, misunderstood, and fought across roughly four thousand years. It starts with the earliest surviving medical descriptions of tumors and runs to the modern era of molecular biology.

The book's ambition is unusual for popular science writing about a single disease. It moves easily between three registers. One is the biography of individual researchers and physicians. Another is the social and political history of cancer research funding in the United States. The third is the underlying science: what a cancer cell actually is, and how it behaves differently from a normal one.

The book is fifteen years old at the time of this page's writing. Cancer treatment has changed a great deal in that period. So this page treats its early and middle chapters as history, and they are largely still accurate as history. The closing chapters describe the treatment landscape as it stood around 2010. Those we treat as dated rather than current.

The book is organized in six parts and moves roughly in order of time. It opens with ancient and early modern descriptions of cancer. One is the Edwin Smith Papyrus, an Egyptian medical text. It describes what appears to be a case of breast cancer, along with the physician's note that there was no treatment.

It then moves through the era of radical surgery in the nineteenth and early twentieth centuries. Next comes the emergence of chemotherapy. That includes the wartime discovery that nitrogen mustard, a chemical weapon, had cancer-killing properties. Then comes the twentieth-century American public health campaign against cancer. That section takes in the 1971 National Cancer Act and the increased federal research funding that followed, often called the war on cancer.

Later sections cover the rise of molecular biology. Researchers came to understand cancer as a genetic disease, and discovered oncogenes and tumor suppressor genes. The book's closing chapters describe the earliest targeted therapies. Those are drugs designed against a specific molecular abnormality, rather than against dividing cells in general. The examples used were current at the time of writing.

The book is strongest as history. In particular, it shows how much of what we now take for granted about cancer took decades to establish, through many wrong turns. We take for granted that cancer is a genetic disease. We take for granted that different cancers respond to different treatments. And we take for granted that population-wide screening and prevention can meaningfully change outcomes. None of that was obvious.

It is also unusually good at making the human cost of scientific uncertainty visible. Some chapters cover early, aggressive surgical approaches. Others cover high-dose chemotherapy regimens later shown to be no more effective than gentler ones. Both describe real harm done in good faith, before the evidence existed to know better. Serious, well-intentioned people made those mistakes with the information they had. That honesty is one of the book's most valuable qualities. It is also a useful frame for a reader trying to understand why cancer treatment recommendations sometimes change.

Its account of the political and funding history behind cancer research is a genuine contribution too. The 1971 National Cancer Act is the clearest case. The book explains why the United States built the research infrastructure it now has, including the National Cancer Institute's expanded role. That connects directly to how cancer research and care are organized today.

The book's final chapters describe the treatment landscape as of around 2010. They are now the most dated part of the book by a wide margin. NCI describes immunotherapy as helping the immune system better act against cancer. It gets relatively little attention in the book. Biomarker testing to choose targeted treatment is now part of care for many patients, and NCI describes it on its targeted therapy page. A reader using the book to understand current treatment options would be working from a picture that is, in places, more than a decade out of date.

Its statistics have the same problem. They describe cancer incidence and mortality trends as understood around 2010. NCI reports that the overall US cancer death rate has declined since the early 1990s. Current figures should come from NCI directly, not from the book's own numbers.

The book is also, by design, a history of cancer as understood and treated in the United States and Western medicine. It does not cover cancer care and outcomes globally in comparable depth. A reader who wants a global picture of cancer burden and treatment access will need other sources.

It is a long book, running past five hundred pages. Its density is deliberate rather than a flaw. But it does mean the book is not the fastest source for a reader who wants a quick answer to a specific question. Someone newly diagnosed, looking for immediate practical guidance about their own treatment, will do better starting with a source built for that purpose. This book can wait until the immediate practical questions are handled, if it is needed at all.

The book's central scientific claim is that cancer is fundamentally a disease of gene mutation. That remains accurate. It is where the book holds up best. It is worth stating NCI's own current version of that claim directly. It is the same underlying idea the book spends hundreds of pages establishing historically.

NCI states plainly that cancer is a genetic disease. It is caused by changes to genes that control how cells grow and divide. NCI identifies three broad categories of genes involved. Proto-oncogenes can become cancer-driving oncogenes when mutated. Tumor suppressor genes act as a normal brake on cell division, and losing them removes that brake. DNA repair genes, when they fail, allow other mutations to pile up. NCI also notes several sources for these mutations. Some are errors during ordinary cell division. Some come from damage by environmental exposures, such as chemicals in tobacco smoke or ultraviolet light. And some are inherited from a parent.

One thing has moved a great deal since the book came out. It is what can be done once a cancer's specific genetic changes are known. Mukherjee's book describes the earliest targeted therapies as a promising but young approach. NCI describes biomarker testing as testing your cancer for targets that could help choose your treatment. Ask your care team whether it applies to you. The book was written at the start of that shift, and could only anticipate it.

The book's own historical arc leads toward a statement about progress. So it is worth checking that claim against current NCI data rather than the book's own figures.

NCI's current cancer statistics page states that the overall US cancer death rate has declined since the early 1990s. It continued to fall in the most recent reporting period. NCI gives the decline as 1.7 percent per year among men and 1.3 percent per year among women from 2018 to 2022. NCI notes that smoking rates, a major cause of cancer, have declined, and that death rates dropping faster than incidence may show the availability of better treatments.

That is not a small correction to the book's narrative. It is closer to a continuation of it. The book ends on cautious, historically grounded optimism about the direction of cancer research. The fifteen years of declining mortality since then broadly support that optimism. The specific treatments the book calls cutting-edge have since been supplemented, and in some cases superseded, by newer approaches.

It is worth being specific about what that decline does and does not mean. A falling national death rate reflects population-level trends across all cancer types combined. It does not mean every cancer type has improved equally. And it says nothing directly about any one patient's prognosis. That depends on the specific type, stage, and biology of their disease, not on a national average.

For a current, detailed picture of how a cancer diagnosis is staged and treated today, see cancer staging and targeted therapy. For one of the clearest single examples of that shift, see The Philadelphia Chromosome.

It suits a reader who wants real depth on cancer's history. It explains how the current landscape of research, funding, and treatment came to look the way it does. Its combination of narrative skill and genuine scientific grounding is rare. It remains a good introduction to cancer as a subject for a reader with no clinical background.

It is not the right source for current treatment information. It is not the right source for current statistics either. And it does not give an up-to-date picture of what a specific diagnosis means today. A reader who has just been diagnosed should treat this book as background and context. It is useful for understanding how we got here. For anything specific to their own care, they should go to current clinical sources, including this site and NCI directly.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• The Emperor of All Maladies — publisher's page (Simon & Schuster)
• NCI — What Is Cancer?
• NCI — Cancer Statistics
• NCI — Risk Factors for Cancer

This page discusses The Emperor of All Maladies for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.